Abstract
The medical management of pituitary tumors is entering a new era. Novel compounds that directly target the pituitary tumor have shown promise in patients with treatment-refractory or recurrent Cushing disease and acromegaly. Furthermore, the alkylating agent temozolomide provides clinical benefit for patients with aggressive pituitary adenomas or carcinomas.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.